The apparent effects of ziprasidone on plasma lipids and glucose

Journal of Clinical Psychiatry

Volumn 62, Issue 5, 2001, Pages 347-349

  Kingsbury, S J ^a   Fayek, M ^a   Trufasiu, D ^a   Zada, J ^a   Simpson, G M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; LIPID; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0034975581     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v62n0507     Document Type: Article

References (10)

1. New atypical antipsychotic medications
2. Antipsychotic-induced weight gain: A comprehensive research synthesis
3. Novel antipsychotics and new onset diabetes
4. Olanzapine increases weight and serum triglyceride levels
5. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses
6. Clozapine-associated elevation in serum triglycerides
7. Diabetogenesis and ketoacidosis with atypical antipsychotics
8. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
9. Improvement in markers of health status six weeks after switching from olanzapine to ziprasidone